Completed

HyperArc Registry Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Brain Diseases+5

+ Brain Neoplasms

+ Central Nervous System Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: March 2022
See protocol details

Summary

Principal SponsorVarian, a Siemens Healthineers Company
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 31, 2022

Actual date on which the first participant was enrolled.

A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Concerns about complexity, patient safety, cost, and human resources can make SRS challenging. HyperArc radiotherapy addresses these challenges by introducing key technology and workflow elements to streamline multi-leaf collimator-based, non-coplanar SRS. HyperArc is designed to deliver SRS treatments from the TrueBeam linear accelerator platform. The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Official TitleHyperArc Registry Study
NCT05270707
Principal SponsorVarian, a Siemens Healthineers Company
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

968 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Brain DiseasesBrain NeoplasmsCentral Nervous System DiseasesNeoplasmsNeoplasms by SiteNervous System DiseasesNervous System NeoplasmsCentral Nervous System Neoplasms

Criteria

Inclusion Criteria: * Received or scheduled to receive treatment using the HyperArc treatment method * Age of legal adult according to local law * Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board Exclusion Criteria: * None, apart from not meeting Inclusion Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 7 locations

Suspended

University of Alabama

Birmingham, United StatesOpen University of Alabama in Google Maps
Suspended

Icon Cancer Centre Canberra

Bruce, Australia
Suspended

Icon Cancer Centre Greenslopes

Greenslopes, Australia
Suspended

Icon Cancer Centre Maroochydore

Maroochydore, Australia
Completed7 Study Centers